Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBMAOZ)

DTT Name Regulatory protein unspecific (RGP)
Gene Name RGP
DTT Type
Clinical trial target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T40663

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teplizumab DMZ3P6C Type-1 diabetes 5A10 Approved [2]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Visilizumab DMXYM1H Graft-versus-host disease 4B24 Phase 3 [1]
NI-0401 DMEOLVP Autoimmune diabetes 5A10 Phase 1/2 [3]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEDI-500 DMT3B4G Bone marrow transplantation QB63.6 Terminated [4]
------------------------------------------------------------------------------------

References

1 Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
2 Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
3 Clinical pipeline report, company report or official report of NovImmune.
4 T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13.